Patient must not have had prior immunotherapy or chemotherapy for malignant pleural mesothelioma
Has extensive pleural effusion which occupies greater than % of the total lung volume observed on screening imaging
Prior chemotherapy for pleural mesothelioma
Participants (all indications) with confirmed bilateral pleural effusion and NSCLC participants with confirmed uni- or bilateral pleural effusion by X-ray are not eligible
Patients with active extra-abdominal disease including active malignant pleural effusion; patients who have been successfully treated with neoadjuvant chemotherapy and no longer have (malignant) pleural effusions may be included
No clinically significant pleural effusion
Participants with confirmed bilateral pleural effusion
Patients with non-malignant pleural effusion are eligible\r\n* If a pleural effusion is present, the following criteria must be met to exclude malignant involvement:\r\n** When pleural fluid is visible on both the CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative\r\n** Exudative pleural effusions are excluded, regardless of cytology\r\n** Effusions that are minimal (i.e, not visible on chest x-ray) that are too small to safely tap are eligible
Evident symptomatic pulmonary fibrosis or interstitial pneumonitis, pleural or cardiac effusion rapidly increasing and/or necessitating prompt local treatment within seven days.
For NSCLC, patients with clinical stage IIB-IV patients (American Joint Committee on Cancer [AJCC], th edition [ed.]) are eligible, and for SCLC, limited-stage patients are eligible, if documented to be a candidate for definitive radiation and concurrent chemotherapy in the radiation oncologist or medical oncologist clinic note\r\n* Stage IV NSCLC patients are eligible only if they have a solitary brain metastasis\r\n* Patients with non-malignant pleural effusion are eligible,\r\n** If a pleural effusion is present, the following criteria must be met to exclude malignant involvement:\r\n*** When pleural fluid is visible on both the computed tomography (CT) scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative\r\n*** Exudative pleural effusions are excluded, regardless of cytology\r\n*** Effusions that are minimal (i.e., not visible on chest x-ray) that are too small to safely tap are eligible
Evidence of measurable disease (per Response Evaluation Criteria in Solid Tumors version . [RECIST .]) outside of the peritoneal cavity (ex: mediastinal lymphadenopathy, parenchymal liver metastasis, or symptomatic pleural effusion proven or suspected to be due to cancer)\r\n* Note: Asymptomatic pleural effusion with or without minimal pleural involvement as long as there is no measurable disease outside the peritoneum/retroperitoneum is allowed
Participants with bilateral pleural effusion and NSCLC participants with uni- or bilateral effusion confirmed at screening by X-ray are not eligible
Pleural or pericardial effusion\r\n *Pleural effusions allowed if one of the following conditions are met: ) negative cytology after adequate sampling by thoracentesis ) effusion seen on CT scan but not on chest x-ray and deemed too small to tap under CT or ultrasound guidance
Part B only: Participants must have malignant pleural or peritoneal mesothelioma
Pleural effusion as the only evidence of metastatic disease
Presence of a significant pleural effusion by chest x-ray
A pleural effusion of moderate severity or worse.
No clinically significant pleural effusion
Pleural effusion: when pleural fluid is visible on both CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative; patients with effusions that are minimal (i.e. not visible on chest x-ray) or that are too small to safely tap are eligible
A pleural effusion of moderate severity or worse.
No clinically significant pleural effusion
Patients must have a histologic diagnosis of malignant pleural mesothelioma
Histologically proven malignant pleural mesothelioma MPM that is considered resectable according to the following criteria:\r\n* Confined to one pleural space\r\n* No chest wall invasion\r\n* No transdiaphragmatic involvement\r\n* No invasion of mediastinal structures
No pleural or peritoneal serous effusion.
Surgically resectable malignant pleural mesothelioma (MPM) with no disease extension beyond the ipsilateral hemithorax
Presence of pleural effusion
If a pleural effusion is present and visible on both CT scan AND chest x-ray, the investigator should exclude malignant disease by pleurocentesis to confirm cytologically-negative pleural fluid; if fluid is exudative or cytologically positive for tumor cells, patient is excluded\r\n* Patients with effusions that are minimal (i.e. not visible on chest x-ray) and that are too small to safely tap are eligible
Prior nephrectomy on the contralateral side of malignant pleural mesothelioma (MPM)
Measurable disease as per Response Evaluation Criteria In Solid Tumors (RECIST) v. criteria or non-measurable disease with symptomatic malignant pleural effusion or malignant ascites; if only site of disease is a pleural effusion, cytologic confirmation of recurrence should be obtained
Clinically significant pleural effusion that either required pleurocentesis or is associated with shortness of breath.
Clinically significant pleural effusion
Exudative pleural effusion, regardless of cytology
Pleural effusion that cannot be controlled with appropriate interventions
Pleural effusion requiring active medical management
Cytologically positive pleural effusion
Pleural effusion that cannot be controlled despite appropriate interventions
If a pleural effusion is present, the following criteria must be met at registration to exclude malignant involvement (incurable Ma disease):\r\n* When pleural fluid is visible on both the CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative\r\n* Effusions that are minimal (i.e. not visible under ultrasound guidance) and that are too small to safely tap are eligible
If a pleural effusion is present, the following criteria must be met to exclude malignant involvement (incurable Ma disease):\r\n* When pleural fluid is visible on both the CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative\r\n* Exudative pleural effusions are excluded, regardless of cytology\r\n* Effusions that are minimal (i.e. not visible under ultrasound guidance) that are too small to safely tap are eligible
Malignant pleural effusion
Patients must have histologically or cytologically-proven new diagnosis of unresectable stage IIIA/IIIB*, non-small cell lung cancer (adenocarcinoma, bronchioloalveolar cell carcinoma, large cell carcinoma, squamous cell carcinoma, or mixed)\r\n* Per the American Joint Committee on Cancer (AJCC) th edition, pleural and pericardial are now considered stage Ma disease; when pleural fluid is visible on the computed tomography (CT) scan or on a chest x-ray, a thoracentesis is required to confirm that the pleural fluid is cytologically negative; patients with exudative pleural effusions are excluded, regardless of cytology; patients with effusions that are minimal (i.e. not visible on chest x-ray) that are too small to safely tap are eligible; a small effusion that has positive fludeoxyglucose F  (FDG) uptake on positron emission tomography (PET) has to be proven to be malignant per standard of care diagnostic procedures for the patient to be excluded
Stage IIIB with malignant pleural effusion/pleural seeding or stage IV histologically confirmed NSCLC
Patients with a pleural effusion that is a transudate, cytologically negative and non-bloody are eligible if the radiation oncologists feel the tumor can still be encompassed within a reasonable field of radiotherapy; if a pleural effusion can be seen on the chest computed tomography (CT) but is too small to tap, the patient is eligible
Pleural mesothelioma basket:\r\n* None
predominantly epithelial (?% tumor component) pleural or peritoneal mesothelioma
Any clinically significant pleural or peritoneal effusion that cannot be drained with standard approaches; an indwelling drainage device placed prior to enrollment is acceptable
Diagnosis of histologically or cytologically documented, malignant pleural effusions (primary non-small cell lung carcinoma, mesothelioma, and other histologies), who have free pleural space (partial or total) that permits the intrapleural drug instillation; this includes cytologically negative pleural effusion in conjunction with histologically proven malignancy involving the pleura
Histological documentation of malignant pleural mesothelioma (MPM) overexpressing mesothelin
Have clinically significant and/or malignant pleural effusion (pleural effusions that are not clinically significant are allowed, defined as no more than % fluid level of the corresponding hemithorax and stable fluid level [non-progressive] over at least  weeks documented radiographically)
Documented extensive disease, defined as any tumor beyond the above limited disease definition, including ipsilateral lung metastases and malignant pleural effusion.
Have clinically significant and/or malignant pleural effusion
Pleural effusion large enough to be detectable on chest x-ray
Patients with a pleural effusion which is a transudate, cytologically negative and non-bloody are eligible if the radiation oncologist feels the tumor can be encompassed within a reasonable field of radiotherapy; patients with exudative, bloody, or cytologically malignant effusions are not eligible; if a pleural effusion can be seen on the chest CT but not on CXR and is too small to tap, the patient will be eligible
For metastatic solid tumors with documented malignant pleural and/or peritoneal effusions, patients must not be receiving specific therapy for the effusion or have an indwelling drain.
Patients with any pulmonary infiltrate including those suspected to be of infectious origin. Exception: Patients with a pleural effusion related to the disease under study as confirmed by the investigator are permitted to enter the study
Histopathologically-confirmed diagnosis of malignant mesothelioma (pleural or peritoneal). Must have disease that has relapsed following at least one prior line of chemotherapy.
Patients with a pleural effusion, which is a transudate, cytologically negative and non-bloody, are eligible if the radiation oncologist feels the tumor can be encompassed within a reasonable field of radiotherapy
If a pleural effusion can be seen on the chest CT but not on chest x-ray and is too small to tap, the patient will be eligible; patients who develop a new pleural effusion after thoracotomy or other invasive thoracic procedure will be eligible
Pleural effusion large enough to be detectable on chest x-ray (CXR)
Free flowing pleural effusion requiring management by placement of a pleural catheter; patients with a functional pleural catheter already in place are eligible for the study, as long as there are no clinical concerns of infection
No free-flowing pleural effusion
Clinically significant pleural effusion.
Clinically significant pleural effusion
Presence of tumor metastases causing significant pleural disease/effusion unilaterally or bilaterally (significant pleural effusion is defined by need for thoracentesis more frequently than once every  days)
Malignant pleural effusion or pleural disease
Malignant pleural effusion that is recurrent
Clinically significant and/or malignant pleural effusion
Any cause of dyspnea that is determined by the investigators as readily reversible by other means (e.g. pleural effusion, pulmonary embolism, acute infection, anemia hemoglobin [Hb] < ., etc.)
Have clinically significant and/or malignant pleural effusion
Pathologic diagnosis of malignant pleural mesothelioma (MPM) confirmed at participating institution
Pleural effusion requiring thoracentesis within  week of study enrollment or scheduled during the study period
Subject has a symptomatic malignant pleural effusion requiring intervention; for an effusion to be defined as malignant, at least one of the following must be true\r\n* There is cytological confirmation of pleural malignancy\r\n* The effusion is an exudate (per Lights criteria) in the context of histocytologically proven malignancy elsewhere, with no other clear cause for fluid identified
Subject has sufficient pleural fluid to allow safe insertion of an indwelling tunneled pleural catheter as determined by the principal investigator (PI)
Radiographic evidence of brain metastases and/or ipsilateral lung metastases/malignant pleural effusion
Patients with minimal pleural effusion evident on chest X-ray (CXR); minimal pleural effusion visible on chest CT is allowed
Known re-expandable lung:\r\n* History of recurrent transudative (by Lights criteria) pleural effusions of known etiology, AND\r\n* Has undergone multiple prior thoracenteses, without history of significant chest discomfort, AND\r\n* Strong clinical suspicion that the current effusion is uncomplicated and due to the known underlying etiology
Pleural effusion is smaller than expected on bedside pre-procedure ultrasound
More than  biopsy on the same side requiring more than  pleural puncture
There is histocytological confirmation of pleural malignancy
A CXR shows ?% of the affected hemithorax to be occupied with pleural fluid AFTER a pleural aspiration which resulted in symptoms suggestive of trapped lung (e.g., chest pain or cough).
Patients with symptomatic pleural effusion requiring placement of an indwelling pleural catheter (IPC) or new placement of an IPC.
Patients with a pleural effusion that is a transudate, cytologically negative and non-bloody are eligible if the radiation oncologists feel the tumor can still be encompassed within a reasonable field of radiotherapy; patients with exudative, bloody, or cytologically malignant effusions are ineligible; if a pleural effusion can be seen on the chest computed tomography (CT) but not on chest x-ray (CXR) and is too small to tap, the patient will be eligible
Tumor with pleural contact.
Patients with non-measurable non-evaluable lesions such as pleural effusion are not eligible to participate
No clinically significant pleural effusion
